Kevin Quon
Insider ownership, small-cap, long-term horizon, dividend investing

Enanta Pharmaceuticals: A Potential Play On Drug-Resistant Bacteria

There are very few companies that are currently carrying out research into new antibiotics. Much of this is due to the fact that this market wasn't as valuable in comparison to other diseases. As it stands now, there are many treatments available. However, drug development decisions must often take place several decades in advance. Additionally, the risk of new drug resistant bacteria is only beginning to grow as the scope of the problem was only realized in the past few years.

One company looking to address this growing issue is an early development company named Enanta Pharmaceuticals, Inc. (ENTA). Enanta is an biotechnology company focused on the research and development of small molecule drugs. The company's primary...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
Money back guarantee. Seeking Alpha PRO members receive a no-questions-asked refund for membership on months paid and not used. Details